CT 03 programme - Captor Therapeutics
Alternative Names: CT-03; CT-03 degraders; CT-03 projectLatest Information Update: 28 Oct 2025
At a glance
- Originator Captor Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action MCL1 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Oct 2025 No recent reports of development identified for preclinical development in Haematological-malignancies in Poland
- 28 Oct 2025 No recent reports of development identified for preclinical development in Solid-tumours in Poland
- 26 Oct 2022 Pharmacodynamics data from preclinical trial in Haematological malignancies presented at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2022)